GNMX 2.25 PHILADELPHIA, PA--(Marketwired - Mar 20, 2017) -
Trial did not meet primary endpoint (overall ADHD-RS), however showed encouraging trend in improvement at highest dose (400 mg BID) Strong trend of efficacy in ADHD-RS inattention subscale (p=0.0515 vs placebo) Strong trend of efficacy in ADHD-RS inattention subscale (p=0.0515 vs placebo) Clear signal of efficacy and benefit to patients ADHD-RS response rate 70% (p=0.0067 vs placebo) CGI-I response rate 57% (p=0.0155 vs placebo) ADHD-RS response rate 70% (p=0.0067 vs placebo) CGI-I response rate 57% (p=0.0155 vs placebo) Well tolerated with no serious adverse events Conference call scheduled for 8:30 AM ET http://finance.yahoo.com/news/aevi-genomic-medicine-provides-top-110000841.html
Always consult an Investment Professional, all communications about stocks from me are my own opinions, and not for investing decisions
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.